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Abstract: The life sciences are having a significant impact on the organisation 
and management of R&D in large pharmaceutical firms, as well as 
restructuring the markets for new therapeutic products. However, there is 
continuing scepticism about large firms’ ability or inclination to build in-house 
capacity for biologics and extract value from the life sciences. This paper 
explores the effect of life science innovation on early and late-stage R&D, and 
considers the implications for strategic management and the transition of 
compounds through the middle stages of the R&D pathway. The analysis, 
which includes two company case studies, reveals that new life science 
technologies have had a marginal impact on late-stage R&D, but companies  
are exploring new organisational or translational models to better exploit the 
science and reduce the phase 2 attrition rates. Findings suggest that firms have 
the capability to adapt to a new innovation trajectory, but external pressures on 
strategic and organisational management will continue to determine the level 
and rate of success. 
Keywords: pharmaceutical industry; life sciences; innovation; strategic 
management; R&D; translational medicine; biotechnology; organisation. 
Reference to this paper should be made as follows: Mittra, J. (2008) ‘Impact of 
the life sciences on organisation and management of R&D in large 
pharmaceutical firms’, Int. J. Biotechnology, Vol. 10, No. 5, pp.416–440. 
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focused on the impact of the life sciences on the evolution of the 
pharmaceutical industry, regulation and policy processes for new technologies, 
such as stem cells and developments in the emerging field of translational 
medicine. He is also part of the course development team for the University of 
Edinburgh’s first online postgraduate course in Translational Medicine. 
 
1 Introduction 
New discoveries in life science are having a significant impact on innovation in the 
pharmaceutical and health-related industry sectors. The promise of genomics and related 
areas of fundamental science is that drug discovery and approval processes will be 
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expedited, and that drugs will become more cost-effective and of greater therapeutic 
benefit to patients. The complexity of the biomedical paradigm, and the significant but 
diverse implications biotechnology and genomics have for various parts of the R&D 
pathway, has created intricate innovation systems and networks (Chiesa and Toletti, 
2004; Dosi et al., 1988; Edquist, 1997). Large, incumbent pharmaceutical companies are 
increasingly reliant on the knowledge, products and expertise of external innovators as 
their traditional capabilities in small molecule drug development no longer appear 
sufficient to sustain productivity (Mittra, 2007). However, there is emerging scepticism 
about the revolutionary claims made on behalf of the life sciences as pharmaceutical 
companies have failed to deliver radically new therapeutic products following the 
mapping of the Human Genome (Arundel and Mintzes, 2004; Hopkins et al., 2007; 
Mittra, 2005; Nightingale, 2000; Nightingale and Martin, 2004). Questions remain  
about the extent to which large firms have the capability and/or inclination to fully 
exploit the potential of biotechnology and genomics, by restructuring internal R&D 
processes and therapeutic foci, for example, so that high value products are successfully 
delivered to market. 
This paper explores the impact of life science innovation on the changing 
organisation and strategic management of R&D. Methodologically, it draws on the 
author’s original interview data from senior scientists and managers within large 
pharmaceutical companies; secondary commercial data on technologies and therapeutic 
trends and two rich company case studies that illustrate different strategies for 
responding to innovation deficit through the exploitation of translational research 
models.1 This paper reveals both endogenous and exogenous commercial and 
technological challenges facing large firms, which impact on their ability to successfully 
exploit emerging biomedical knowledge and new translational processes for drug 
discovery and development. The data suggest that new technologies have created 
economies of scale in early-stage R&D yet, despite huge investment in biotechnology 
and genomics, the perception of innovation and productivity deficit remains prevalent. 
Furthermore, the attrition rate of compounds in phase 2 is significant and has induced 
firms to experiment with creative organisational strategies. Industry is optimistic that 
decentralised R&D models, coupled with a reassessment of conventional technological 
and therapeutic priorities, will enable it to successfully respond to challenges posed by 
tumultuous social, technological and commercial externalities. The concept of 
‘translational medicine’ is increasingly being used to describe these new organisational 
processes for expediting the movement of compounds from ‘bench to bedside’  
(Horig and Pullman, 2004; Mankoff et al., 2004). 
This paper is structured as follows. Section 2 illustrates the key changes that have 
taken place in pharmaceutical innovation and some of the generic challenges facing large 
firms. These challenges have provided the primary impetus for major organisational 
restructuring and experimentation with new technologies and strategic management 
options. Following from this, in Section 3, I explore large firms’ investment in life 
science technologies as a means of exploiting economies of scale and scope in the 
discovery and early stage development of novel compounds. Interview data reveal how 
firms have responded to the transformative potential of the life sciences and uncover 
scientists and managers’ perspectives on the future commercial benefits and key 
innovation bottlenecks. One main finding is that new technologies have not yet yielded 
significant returns in late-stage R&D, and important questions remain about firms’ ability 
to extract optimal value from the life sciences. Section 4 presents two company case 
studies that highlight some of the different ways in which large firms are exploiting new 
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organisational and strategic management options to sustain innovation and reduce the 
attrition rate of novel therapeutic compounds. The first case study explores the 
reorganisation of R&D at GlaxoSmithKline; specifically the implementation of 
decentralised Centres of Excellence for Drug Discovery (CEDD). The second case study 
looks at the recently established Translational Medicine Research Collaboration 
(TMRC); a novel public–private partnership involving the global pharmaceutical firm 
Wyeth, Scottish Enterprise (a regional development agency), four Scottish universities 
and the NHS in a collaborative search for novel biomarkers. In Section 5, I critically 
explore some of the broader implications of these diverse organisational models and 
strategic choices for the future of ‘Big Pharma’ and therapeutic innovation. 
2 The changing face of pharmaceutical innovation and  
key challenges facing industry 
The pharmaceutical industry is an innovation-driven, R&D intensive sector susceptible  
to ‘technological shocks’ in the form of new scientific paradigms and path breaking 
technologies; where strategic options are shaped by a strong regulatory regime that  
exists outside the core innovation system (Tait, 2007). The success of multinational 
companies depends on a continual flow of new, innovative, preferably small-molecule 
‘blockbuster’ therapies to sustain revenue growth. Genomics and biotechnology-related 
technologies and approaches that have or could transform pharmaceutical innovation 
include: 
1 automated high-throughput screening and combinatorial chemistry to increase 
the rate of discovery for New Chemical Entities (NCEs) 
2 systems biology and bioinformatics databases to aid understanding of the 
genetic basis of disease, which requires closer collaboration between medicinal 
chemists, biologists and IT specialists 
3 pharmacogenetics to screen potential drug candidates and improve their safety 
and efficacy profile before they enter clinical development 
4 recombinant proteins, monoclonal antibodies, peptides and large, organic 
molecules as drug candidates, which may require radical rather than incremental 
changes in manufacturing, regulation and distribution processes. 
Here, one must distinguish large, protein-based molecules from new small molecules in 
terms of their impact on conventional innovation processes.  Companies have attempted 
to apply these techniques to various stages of R&D, although the most significant 
changes have been in the discovery and preclinical phases. This will be elaborated 
further in the following section. 
Before the emergence of the life sciences, and the expectations and ‘promissory 
visions’ it offered to industry (Borup et al., 2006), conventional, chemistry-based 
pharmaceutical R&D rested largely on serendipity as companies would screen known 
compounds stored in their extensive chemical libraries. Lead molecules would then be 
optimised by medicinal chemists to produce potential drug candidates; the most 
promising of which would then be moved to late-stage development and finally  
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to market. In the 1980s and 1990s, the R&D process was advanced considerably with the 
advent of molecular biology, synthetic chemistry and improvements in the development 
of screening technologies. These techniques increased the rate at which new molecular 
entities could be discovered and furthered industry’s knowledge of disease and drug 
targets (Ratti and Trist, 2001). High capacity screening and better target identification 
and validation tools were invaluable to the pharmaceutical industry during this period. 
Nightingale (2000) suggests that biotechnology helped create ‘economies of scale’  
in R&D as new technologies allowed companies to significantly increase screening 
capacity with less human resource and thus reduce the overall operating costs of  
drug discovery. He argues that both chemistry and biology shifted from essentially  
craft-based, sequential processes on single compounds to automated mass-production 
processes conducted in parallel. 
The development of a wide range of life science technologies to improve the R&D 
process, and exploitation of a more rational approach to drug design, engendered a 
broader restructuring of the pharmaceutical industry (Drews, 2000; Mittra, 2007).  
In particular, large, vertically integrated pharmaceutical firms came to increasingly 
depend on the knowledge, expertise and products of external innovators, such as the new 
dedicated biotechnology firms and academic research institutions (Mittra and Williams, 
2007). New technologies engendered significant organisational restructuring and 
subsequent changes in the innovation value chain (Quéré, 2003). Pharmaceutical R&D 
became characterised as a distributed or networked innovation system (Cambrosio et al., 
2004; Chiesa and Toletti, 2004), in which the incumbent firms began increasingly to 
exploit merger and acquisition activity, strategic alliances, outsourcing and licensing 
models to sustain innovation (Crossley and Kordel, 2002; Langley et al., 2005; Mittra, 
2007; Tait and Mittra, 2004). Coombs and Metcalfe (2002) suggest that large 
pharmaceutical firms now had to create, coordinate and combine a diverse range of 
research and development ‘capabilities’, alongside the normal processes of organic 
growth, to remain competitive and profitable. 
Although the life sciences have provided the pharmaceutical industry with new 
strategic options and dynamic technological capabilities (Hilliard and Jacobson, 2003; 
Teece et al., 1997), it is important to recognise that the reshaping of the industry, and 
experimentation with new organisational models, has taken place in the context of much 
broader social, commercial and technological challenges. Despite the development of 
new technologies, and the potential panacea they promised to an industry that must 
continually innovate to survive, a number of internal and external factors threaten to 
undermine large firms’ historic dominance in therapeutic innovation. In summary,  
the key challenges include: 
Decline in R&D productivity: despite year-on-year increases in R&D expenditure, the 
pharmaceutical industry is plagued by a productivity crisis and a widespread perception 
of innovation deficit (Drews and Ryser, 1996). Although overall investment in 
pharmaceuticals tripled during the 1990s to more than $30 billion, a declining number of 
new therapies were approved by regulators and placed within the market. Figure 1 
reveals the number of NCEs approved by the FDA between 1987 and 2003, and Table 1 
shows the domestic and total R&D spend as a percentage of sales for PhRMA member 
companies from 1971 to 2003. 
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Figure 1 NCE approvals 1987–2003 
 
Source: FDA and Deutsche Bank AG Report. 
Table 1 R&D as a percentage of sales: PhRMA member companies 1971–2003 
Year Domestic R&D as % of domestic sales Total R&D as % of total sales 
2003 18.3 15.7 
1999 18.2 15.5 
1995 20.8 16.7 
1991 17.9 14.6 
1987 17.4 13.4 
1983 15.9 11.8 
1979 12.5 8.6 
1975 12.7 9.0 
1971 12.2 9.0 
Note: This data only shows R&D and sales within the USA. 
Source: Adapted from PhRMA annual membership survey 2005. 
Despite a peak in 1996, the number of approvals has been in general decline ever since. 
Furthermore, the number of new active compounds discovered by large pharmaceutical 
firms has remained relatively constant at 4–6 per year, despite significant advances in 
screening technologies and generally increased R&D expenditure until the mid 1990s, 
when internal R&D spend appeared to level off. This may be indicative of an increase in 
R&D outsourcing and/or higher reliance on licensing strategies from 1995.  With few 
exceptions, most of the major, vertically integrated pharmaceutical firms are no longer 
generating in-house a sufficient number of new compounds to sustain revenue growth 
(Horrobin, 2001). 
High attrition rate: although there has been great investment in new technologies, 
there continues to be a high attrition rate in pharmaceutical R&D, particularly in the 
middle stages of the R&D process and phase 2 clinical studies, where the success rate has 
been as low as 20%. Lack of demonstrable safety and efficacy appear to be the primary 
causes of attrition. Currently, only one in two compounds that enter phase 3 clinical  
trials eventually reaches the market. Reasons for the high attrition rate include: the 
complexity of the science and limited understanding/validation of new drug targets;  
a robotic approach to R&D has replaced a more intellectual approach (Drews and Ryser, 
1996) and large firms face substantial problems of resource allocation and portfolio 
management. The bureaucratic organisational structure of large companies makes it 
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difficult for them to be nimble and reactive to new and potentially disruptive 
technological paradigms. As the small-molecule innovation model has reached a level of 
maturity, all the simple drug targets have already been discovered and are now coming 
off-patent. Companies must better utilise new technologies, innovative science and 
organisational capabilities to mitigate the attrition and productivity crisis. 
Rising cost of drug discovery: new methodological approaches; internationalisation 
of research; integration of new disciplines/technologies (Howells, 2002) and successful 
knowledge management add to the overall costs of drug discovery. The cost for a large 
pharmaceutical firm to bring one product to market has been estimated to be around  
$800 million (DiMasi et al., 2003). There are also increasing demands from regulators 
and healthcare providers to improve safety and efficacy and reduce the price of new 
innovative drugs in response to rising stakeholder expectations. Controversies over 
clinical trial data (McCrea and Markle, 1984), the safety of medicines and their 
therapeutic value (Abraham and Davis, 2007) and pharmaceutical firms’ ostensible 
influence on regulatory processes (Kerridge et al., 2005; Sweet, 2004) are becoming 
increasingly common. The necessarily high ‘regulatory hurdle’, and often capricious 
nature of policy and regulation for new pharmaceutical products, continues to render 
fully integrated therapeutic R&D prohibitively expensive for all but the largest 
companies. Regulation has been shown to have a direct and significant effect on drug 
lead times and R&D performance (Dove, 2003; Hartley and Maynard, 1982) and limits 
the ability of ‘new entrants’ to compete effectively with the incumbent multinationals 
(Tait, 2007). Of course, some genomics-based companies have been successful in 
transforming themselves into competitive, fully integrated drug development companies 
(Rothman and Kraft, 2006), but they continue to be the exception rather than the norm. 
Continued reliance on ‘blockbuster drugs’: although new life science technologies 
provide an opportunity to develop more targeted therapies for niche markets,  
the traditional blockbuster model of drug development remains prevalent amongst the 
larger firms. Companies continue to focus on a narrow range of therapeutic areas that 
generate high value and high demand products. Figure 2 provides data on the 
pharmaceutical market by therapeutic category, which suggests that large firms must 
have a strong presence in at least three or four key markets if they are to remain 
competitive and sustain revenue growth. 
Figure 2 Pharmaceutical market by therapeutic category 
 
Source: IMS Health and Deutsche bank estimates. 
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Consequently, the pharmaceutical market continues to be saturated with ‘me-too’ 
therapies or ‘incremental innovations’ in core therapeutic franchises, rather than ‘first in 
class’ products for a broader range of disease indications. Although there is a growing 
belief that the blockbuster model is unsustainable, no effective alternative has yet 
emerged. The expiry of many patents on existing blockbuster drugs is also amplifying 
concerns over productivity. Furthermore, the high cost to firms of traversing the 
increasingly onerous regulatory system means that the search for blockbuster therapies 
continues at present to be the only realistic strategy for a large firm to pursue. 
Together, these industry challenges are fundamentally affecting the evolution of the 
pharmaceutical sector, as well as the strategic management of internally- driven R&D 
within individual companies. Firms must experiment with new technologies and 
managerial approaches to sustain innovation in the context of a turbulent social, political 
and commercial environment. The following sections elaborate these key issues in the 
context of specific firms’ managerial and organisational stratagems. 
3 Extracting value from new life science technologies:  
the experience of large firms 
The interview accounts of senior scientists and managers in large pharmaceutical 
companies reveal the fundamental changes that have taken place in the R&D process. 
Respondents countenanced the view that new technologies had helped create economies 
of scale in early stage R&D and rendered parts of the research endeavour more efficient 
by facilitating better capacity utilisation. A number of specific technologies were cited by 
respondents as having been particularly auspicious for early-stage R&D. 
Firstly, general automation technologies, such as combinatorial chemistry and 
automated synthesis, have allowed large firms to increase the number of potential small 
molecule compounds available for downstream development. This has engendered a 
move away from the conventional craft-based design of single molecules to parallel, 
high-throughput screening processes. On the biological side, according to one 
respondent, 
“there have been massive strides in trying to break down the process and 
identify the involvement of particular targets, enzymes and receptors in 
diseases and screening for them in a much more controlled way.” (Portfolio 
Manager, INT3/Company B) 
These approaches have been exploited for both new biological and conventional  
small-molecule chemical entities. In one sense, automation technologies have enabled 
companies to disaggregate the components of biological and chemical systems – a highly 
reductionist approach – and generate high-level data to support candidate selection and 
optimisation. Another respondent stated: 
To make a molecule which is selective, has the right pharmacology and is 
potent at its target is a process which is much quicker and much slicker than it 
was before. We are also beginning now – through chemical and in vitro 
methods – to address issues such as metabolism, which is now handled quite 
early in the process so that failures due to poor kinetics and metabolism in man 
have really decreased a lot over the last 10 years (Head of Neuroscience, 
INT9/Company D). 
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The availability of a broad spectrum of automation technologies – a large number 
developed by small and medium sized platform technology firms – have, according to 
interview respondents, significantly advanced the discovery and selection of viable 
therapeutic compounds. 
Secondly, technologies such as X-Ray crystallography and electron microscopy have 
been invaluable for improving identification, knowledge and understanding of complex 
biological structures. While automated processes appear to have helped firms discover 
new molecular entities more cheaply and efficiently, these additional technologies have 
made a significant contribution to what is often referred to as rational drug design, which 
requires changes in the nature of R&D and its organisational structure (Cockburn, 2004). 
Respondents considered these technologies to have been particularly important for  
small-molecule drug development, as they have provided knowledge and understanding 
that have allowed organic chemists to design molecules that interact with specific  
drug targets in more predictable and efficacious ways. One respondent claimed that these 
technologies have allowed firms to “move away from the empirically-based approach  
to R&D, which had been very successful, towards a more target-driven, focused,  
disease pathogenesis underpinning” (Head of R&D Policy, INT1/Company 1). Another 
respondent claimed that a variety of analytical technologies, including the development 
of functional assays, had changed beyond all recognition over the past two decades.  
He stated: 
If we synthesise a compound we can identify exactly what it is – its structure 
and everything else – within an hour. Previously we would send it down for 
carbon, nitrogen and oxygen analysis and a week later you’d be able  
to construct an idea of what you’ve made. Analytical technologies have all 
completely moved on in terms of where they were 25 years ago. That really 
does affect our productivity … 25 years ago, mass spectrometry was essentially 
a room; a bloody big magnet that could analyse one compound every hour or 
so. Now a mass spec comes out quickly on a computer and you have lots of 
data available for analysis. These are just amazing changes (Head of Global 
Sciences and Information, INT2/Company B). 
Here, new technologies create greater efficiency in the early-stage development of new 
compounds. Better information about the chemical compound and its biological target, 
which can be accumulated and analysed faster than ever before using a panoply of 
automation and data mining technologies, has enabled companies to improve  
decision making on which compounds to take forward for further development. 
However, this information explosion has also created its own R&D challenge; how best 
to disaggregate the data and identify the useful information that can facilitate strategic 
decision making. 
Finally, developments in DNA Sequencing and functional analysis following the 
mapping of the Human Genome have led to the identification of an increasing number  
of potential drug targets, which include receptors, enzymes and a large number of 
previously unknown proteins (Dahl, 2006). Of course, new targets from cDNA 
sequencing (complementary DNA is DNA synthesised from a mature mRNA template) 
had been identified prior to the completion of the Human Genome Project. Nevertheless, 
the possibility of developing new therapies for thousands of drug targets, rather than the 
500 or so companies had traditionally been restricted to, was extremely attractive to large 
firms as it broadened their options for therapeutic innovation. However, one interview 
respondent stated that although his own company had successfully identified a range of 
new biological targets, it was finding it difficult to validate the targets and develop 
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molecules with the right pharmacological spectrum to interact with them effectively.  
He stated: “What has happened is that we’ve had a number of efforts making molecules 
that don’t actually do anything very exciting in the clinic” (Head of Neuroscience, 
INT9/Company D). Another respondent stated: 
As the technology increased its stronghold in genomics, targets were being 
turned over very rapidly but were non-validated. This significantly impacted 
their efficiency and their value in a negative manner (Former Head of 
Computational Biology, INT8/Company C).  
A major challenge for industry is to design and develop new methods and algorithms for 
data integration and analysis. A former head of bioinformatics at a major pharmaceutical 
firm stated: 
Better hypothesis generation is required so you can rank your targets using the 
software with some plausible guesses if this type is better than others … you 
need to be able to integrate information from three platforms – gene expression, 
proteomics and metabonomics (INT6/Company A). 
Although most of the respondents did believe that new technologies had created greater 
efficiency in early-stage R&D, they were far more circumspect in their assessment of the 
downstream impact of the life sciences. One respondent claimed that although his 
company’s discovery research groups had improved candidate selection by exploiting 
new technologies, “If you ask me have we got anything to show for it yet [in terms of 
radically new therapies], I think I’d be fibbing if I said we had” (Director of Academic 
Liaison, INT9/Company A). Nevertheless, this respondent was optimistic about the 
future potential of genomics. He claimed that the larger firms were beginning to 
accumulate and integrate genomic data in a way that has allowed them to begin 
stratifying certain diseases and their progression at the genomic level. Although it is still 
unclear whether the complex information derived from DNA and tissue studies will be 
successfully translated into useful information for therapeutic development, interview 
accounts revealed that all the major companies are actively collecting DNA and tissue 
samples and utilising biodata in conjunction with conventional wet chemistry. 
Pharmacogenetics is certainly still in its infancy, and may not yet have met the high 
expectations of downstream stakeholders and regulators (Hedgecoe and Martin, 2003), 
but companies appear committed to exploring its potential use in both early and late 
stages of drug development. 
In addition to the specific development and integration of new technologies, there 
have also been substantial process changes in R&D. One respondent claimed that 
activities her company did not traditionally do in the research stage, such as toxicology, 
pharmacokinetics, drug deposition and pharmacodynamic modelling, are now initiated 
before drugs become nominated into development (VP Discovery and External Affairs, 
INT 4/Company B). The ultimate goal for firms is to better predict which compounds are 
likely to progress successfully through the various development phases of R&D.  
If companies can exploit new technologies and frontload some of their existing activities 
to improve decision making on the selection of early-stage compounds, this may help 
reduce the phase 2 attrition rates that continue to plague the industry. 
However, there does remain a number of scientific, technological and commercial 
challenges to the successful exploitation and integration of new life science technologies 
within a conventional pharmaceutical innovation system. Interview respondents were 
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remarkably candid in their assessment of the various R&D bottlenecks within their 
companies. One respondent suggested that there had been a great deal of hype 
surrounding some of the technologies, which later failed to deliver on their early 
promise. He claimed that anti-sense technologies failed to make the grade, and RNAi use 
in vivo is still very much experimental and has an uncertain future. This respondent also 
argued that the Human Genome Project had been a mixed blessing in terms of 
developing new targets for truly innovative drugs. He stated: 
We initially imagined that the human genome was going to have a lot more 
genes than it turned out to have. That makes a big difference because people 
have made estimates of the size of the druggable genome; that is, the numbers 
of proteins belonging to structural classes for which small molecule ligands are 
known (such as G protein-linked receptors or ion channels or kineases). It’s not 
that many, probably about 10%. Three thousand targets isn’t a lot when you 
think we’ve already developed drugs for 500, and of those 3000, many of them 
won’t be involved in any way in modifying disease processes. So the 
pessimistic view is we’ve already mined it out, at least for small molecule drug 
discovery, or we have done all the easy ones and only the hard ones are left.  
If the genome had been 3 times bigger, you wouldn’t have that feeling  
(Former Head of Neuroscience, INT9/Company D). 
The comment that all the easy targets have already been exploited may partly explain 
why it is taking so long to develop the novel therapies that genomics promised to deliver 
and downstream stakeholders increasingly expect. The failure of pharmaceutical 
companies to market the ‘designer drugs’ and personalised therapies for hitherto 
intractable conditions (Joppi et al., 2005), which arouses much excitement amongst the 
media, patient groups and the public, reflects the growing complexity of the innovation 
pathway. The paradigm shift from traditional small-molecule-based therapies to biologics 
has been a slow, evolutionary process within the large firms as they struggle to collect, 
store and interpret the complex data available and identify commercial opportunities 
associated with new innovation trajectories. This partly explains why large firms have 
tended to pursue mergers, acquisitions and strategic alliances with smaller biotechnology 
firms as their primary route to biologics (see Cockburn, 2004; Mittra, 2007). 
Nevertheless, although there has been a trend towards increased sourcing of compounds 
from external innovators, as opposed to internally-driven R&D (Danzon et al., 2004; 
Lane and Probert, 2007), large firms continue to prioritise in-house projects where they 
have strong internal capabilities. Indeed, most of the large multinationals have been 
slowly accumulating internal knowledge, expertise and resource capabilities in 
biotechnology alongside traditional chemistry. The notion that large pharmaceutical 
firms are no longer as innovative as the smaller, entrepreneurial biotechnology 
companies, and perhaps incapable of developing in-house new life science based 
therapies, does not seem to be supported by the evidence (Schmid and Smith, 2005).  
One interview respondent stated: 
There is this kind of urban myth that the pharmaceutical industry is only 
interested in small molecules and doesn’t do anything else, and all the 
innovative stuff comes from little companies. My company is probably one of 
the biggest biotech companies in the sense that it makes biological drugs, and 
always has done, so we don’t make this distinction. An appreciable part of our 
portfolio is proteins, peptides and humanized antibodies, with expertise 
developed over years through making insulin (Head of Neuroscience, 
INT9/Company D). 
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In addition to the problem of data sourcing and interoperability, and how best to identify 
viable commercial options for developing life science-based therapeutics, there is also a 
significant clinical challenge facing contemporary drug developers. As regulators and 
publics demand greater safety and efficacy requirements for new therapies, firms need to 
better integrate clinical and laboratory studies to ensure drugs have the optimal 
pharmacological spectrum and toxicological effects can be predicted with relative 
certainty. In this context, firms are exploring the potential of pharmacogenetics and 
trying to identify novel biomarkers, to facilitate the drug discovery process. However, 
this still requires the successful integration of disparate types of clinical information, 
knowledge and expertise; particularly chemistry, biology and information technology. 
Although firms appear to be developing a more diverse range of internal capabilities and 
interdisciplinary operating conditions, success in terms of new product output has been 
slow to materialise. 
All the interview respondents cited the phase 2 attrition rate, and general inefficiency 
in the middle stages of the R&D process, as the primary challenge currently facing large 
firms. Two primary reasons were given for the high attrition rate and diminished 
productivity. Firstly, increasing expectations of safety and efficacy by regulators  
and healthcare providers has led to the requirement for much larger and better designed 
clinical trials. Problems of patient recruitment and escalating costs of clinical trials have 
directly affected R&D performance. Secondly, the availability of much more clinical 
data and genomic information, which has been welcomed by industry, has also 
contributed to an overall increase in the cost of drug development and slowed down 
certain phases of R&D. Although some parts of R&D have become more efficient, such 
as discovery, preclinical candidate selection and manufacturing, attrition in the middle 
stages of R&D has not improved a great deal. For this reason, companies have begun to 
fundamentally reorganise their R&D operations and management systems, as well as 
explore novel strategic collaborations with external innovators, to extract value from  
the new technologies and exploit what is now conventionally termed ‘translational 
medicine’. 
4 Experiments with new organisational models for pharmaceutical 
R&D and exploitation of public sector resources 
In response to the opportunities and challenges engendered by life science technologies, 
as well as the capricious operating environment for contemporary pharmaceutical R&D, 
companies are exploring new organisational and strategic options for speeding up the 
transition of compounds from the laboratory to the clinic. In this section, I describe and 
critically evaluate two exemplary initiatives that illustrate some of the strategic and 
organisational changes taking place within the large firm sector. The first case study 
looks at GSK’s CEDD, which represents a radical overhaul of internal R&D 
management. The second case study looks at Wyeth’s investment in Translational 
Medicine through a novel Public–Private initiative located in Scotland. Although they 
appear to be very different cases in terms of scale and scope, and many other companies 
are also adopting similar strategies to a greater or lesser extent, these cases do usefully 
illustrate some of the managerial changes and strategic options large companies are 
currently experimenting with. 
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4.1 GSK and the CEDD 
In early 2000, GlaxoSmithKline underwent a major restructuring initiative, led by its 
new CEO Tadataka Yamada, which culminated in a decentralised R&D model as a 
strategic response to the fundamental challenges of modern drug development; in 
particular the phase 2 attrition rate and declining productivity. This section examines the 
implementation of GSK’s CEDD, which signalled a departure from the conventional, 
highly centralised and top-down R&D management model characteristic of most 
multinational pharmaceutical companies. The establishment of the CEDDs was an 
ambitious and high-risk strategy, but GSK believed that these relatively small and 
autonomous units, which attempt to imitate the entrepreneurial spirit of the smaller 
biotech companies, would facilitate the transition of compounds through its R&D 
pipeline. The most significant innovation was that each CEDD would be therapeutically 
aligned and be given decision rights and control over early-stage candidates. However, 
there are important questions about the overall effectiveness of the CEDD strategy, and 
the evolving relationships and knowledge flows between these multihub structures and 
remaining centralised departments within GSK (Criscuolo and Narula, forthcoming).  
It is important to consider the benefits and challenges of R&D diversification for 
innovation and strategic management. 
Initially, discovery scientists at GSK were divided into six CEDDs. A seventh CEDD 
was created later to focus specifically on biopharmaceuticals, which signalled GSK’s 
increasing commitment to life science innovation. More recently, GSK established a 
Centre of Excellence for External Drug Discovery; a virtual organisation that leverages 
external alliances and collaborations. The CEDD strategy emerged from Yamada’s 
growing scepticism with the traditional big pharma model of R&D, particularly  
its reliance on a centralised and bureaucratic decision-making structure and the artificial 
boundary it constructs between the discovery and development phases of R&D.  
This countenances Drews and Ryser’s (1996) argument that traditional pharmaceutical 
firms often lack the organisational and managerial flexibility required in the age of 
complex biomedicine. Yamada stated: 
“There are times in the R&D process where you want to leverage your scale, 
and there are others when you want to be nimble and responsive. For example, 
large pharmaceutical companies are very good at the front-end of drug 
discovery, which often involves capital-intensive, high-throughput screening of 
compounds for activity against a target. They are also very good at the later 
stages of drug development – running large clinical trials and managing the 
FDA approval process. It is the important middle ground of this process – 
converting promising compounds into viable products – where the flexibility 
and responsiveness of smaller biotech firms is essential. The challenge for GSK 
was to put together an R&D organization that benefited from the best 
characteristics that big pharma and smaller biotechs had to offer.” (cited in 
Huckman and Strick, 2005) 
The basic idea was to confront the attrition and productivity problem by creating 
relatively independent, geographically diverse ‘hub’ R&D units that would acquire the 
functions previously held by centralised management systems for the middle stages of 
the R&D process. 
Each CEDD is relatively small (250–350 research scientists) and headed by a senior 
vice president. The research scientists largely comprise biologists and chemists, but the 
CEDDs also include physicians and clinical researchers whose role is to contribute to the 
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design and implementation of preclinical and clinical trials. Clinical experts are essential 
for facilitating the translation of compounds into viable therapeutic products.  
Close collaboration between clinical experts and discovery scientists, and exploitation of  
bi-directional knowledge flows, allows information from preliminary human experiments 
to be fed back to discovery scientists (Horig and Pullman, 2004). Discovery scientists 
can then refine their understanding of the disease model and drug candidate and optimise 
the therapeutic compound for clinical use. To ensure the flexibility and responsiveness of 
the CEDDs, each is engineered to be small, autonomous and able to foster close  
day-to-day interactions amongst its scientists. If the CEDDs were too large and centrally 
controlled, they could become overly bureaucratic and lose the entrepreneurial spirit 
GSK considered essential for the middle stage of drug R&D, which involves candidate 
selection, preclinical/phase 1 and proof of concept studies. The basic structure of the 
CEDD initiative is presented in Figure 3. 
Figure 3 GSK CEDD structure 
 
Source: Created by author using company information. 
In this model, scientists report directly to the leader of their CEDD, as opposed to the 
global functioning areas of GSK. Each CEDD identifies diseases of interest within its 
broad therapeutic remit and then ‘commissions’ GSK’s centralised Genetics Research 
and Discovery Research departments to search for relevant targets and lead compounds. 
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Genetics Research identifies the molecular targets, while Discovery Research applies 
high-throughput screening technologies to isolate lead compounds. At the front-end of 
discovery, GSK also has a Technology Innovation Board (TIB), made up of senior vice 
presidents, which evaluates and benchmarks competing chemical and biological platform 
technologies for possible use by the CEDDs. The CEDDs are not obliged to accept 
suggested lead compounds and are permitted to license-in compounds from external 
innovators if it is within their available budget. 
CEDDs take responsibility for projects at the stage of lead optimisation, performing 
chemical and biological analysis on the compound to evaluate a range of structural 
variations likely to meet the needs of a particular target. Once the compound has been 
optimised, scientists decide whether to progress the compound to preclinical animal 
testing. If preclinical studies are successful, the leader of the CEDD decides whether 
phase 1 clinical trials are to be initiated. This process is conducted independently of the 
centralised departments of GSK. If the compound is still considered viable once proof of 
concept has been established, the CEDD presents the compound to GSK’s centralised 
Development Investment Board (DIB). This is the first point in the innovation life  
cycle where corporate-level R&D executives make decisions about the compound’s 
future. If the board accepts the compound, phases 2 and 3 clinical trials are initiated. 
Since large pharmaceutical companies have historically been best positioned to conduct  
late stage clinical trials and initiate regulatory approval processes, GSK was reluctant to 
relinquish centralised control of this function. 
It must be noted that GSK is not unique amongst the large pharmaceutical firms in 
organising R&D according to therapeutic areas. Furthermore, most large firms now have 
geographically distributed R&D facilities in what might be termed a networked ‘hub 
structure’ (Criscuolo and Narula, forthcoming). However, the managerial innovation was 
in the new operating norms established within the CEDDs. As one interview respondent 
stated: 
The vast majority of large companies will split their R&D on some 
geographical or therapeutic area basis anyway; they don’t tend to just lump it 
all in one building. So it’s kind of a historical trend anyway. But the notion that 
you’re giving your working people more individual responsibility and 
autonomy is new … the notion was that these quasi-independent Centres of 
Excellence could then function to attract funding from outside the company. If 
they weren’t getting what they wanted from discovery research or genetics 
research within GSK, they had a budget and they could go buy it externally 
(Research Scientist, INT7/Company A). 
The purported autonomy to seek external alliances and collaborations, coupled with an 
internally competitive organisational structure, appears to distinguish the CEDDs from 
the more conventional decentralising strategies developed by similar sized firms. 
GSK claims that reducing the layers of management between the leadership team and 
the bench scientists has ‘enabled much earlier go/no go decisions to be made, 
compressing timelines and lowering costs’ (GSK Annual Report, 2006). In 2003, 
Yamada made the following statement on GSK’s website: 
“Our new CEDD structure is working well. We are developing more quality 
compounds than ever before. This is enabling us to renew our pipeline in 
disease areas where we are leaders – like respiratory and psychiatry – and to 
build strong portfolios in areas like oncology and cardiovascular disease.” 
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GSK clearly saw the success of the small biotechnology companies as good reason to 
experiment with a radically new organisational form. The attempt to create independent, 
competitive and close-knit research units, yet allow these networked hubs to exploit the 
expertise, scale and scope of a large firm’s discovery and late-stage development 
capabilities, was a bold and ambitious strategy. However, there are a number of potential 
problems that may undermine this strategy’s long-term success and status as a model of 
best practice for the industry. 
Firstly, CEDDs do not contribute to discovering new targets and have a limited role 
in improving the safety, efficacy and market access to new therapies, functions which 
remain highly centralised. The challenges facing the pharmaceutical industry are much 
broader than mid-stage R&D and many generic problems are likely to persist, 
particularly the regulatory hurdles, challenges of stakeholder expectations and the low 
number of NCEs (relative to R&D investment) being discovered. 
Secondly, the extent to which the CEDDs truly imitate the biotechnology sector is not 
clear. As one commentator has stated: 
“To truly mimic a biotech firm, one might expect these units to be able to go 
off at a tangent if they find something really exciting, and look at niche drugs 
that might be considered too small for GSK itself to bother working on.” 
(Nature Biotechnology, 2001) 
This does not appear to be the case at GSK, since all candidates must be approved at a 
higher corporate level at some point in their life cycle. 
Thirdly, the competitive nature of the CEDDs, which is presented as one of the 
model’s key strengths, could hinder GSK’s ability to exploit similarities of ‘mechanisms 
of action’ across therapeutic areas, and therefore achieve economies of scope in R&D. 
Henderson (2000) argues that it is large, centralised firms that are generally better able to 
exploit internal knowledge spillovers and economies of scope in early-stage R&D.  
Furthermore, the benefits of spillovers can only be acquired if there is a sufficient level 
of ‘absorptive capacity’ (Cohen and Levinthal, 1990), which requires close collaboration 
between different sections of the research organisation. If a compound has therapeutic 
relevance to two disease areas located in geographically diverse and relatively 
autonomous CEDDs, the potential for serendipitous knowledge spillover is reduced and 
the model appears to lose one of the key benefits associated with a large and centralised 
organisational structure. 
Fourthly, it is extremely difficult to evaluate the impact of the CEDDs on GSK’s 
overall productivity. Since they were established, GSK has prosecuted an increased 
number of strategic alliances, small-scale acquisitions and licensing deals. These specific 
strategies, operated through a virtual CEDD, may have had a greater impact on 
productivity than the establishment of the original CEDDs. This virtual CEDD appears 
little different from the external knowledge management departments now common  
in most large firms, but its virtual nature engenders a particular problem for  
innovation. Since it does not conduct any basic research, and appears disconnected from 
the research hubs, it may not have access to sufficient knowledge and expertise to 
evaluate the potential of external innovations and their relevance to core CEDD 
activities. In most firms, research scientists are heavily involved in the development of 
alliances associated with their specific areas of research, but it is unclear to what extent 
this virtual organisation involves scientists from the main CEDDs in its decision-making 
processes. 
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Finally, the very independence of the CEDDs may have negative knock-on effects on 
the centralised discovery unit that feeds it with compounds. As one interview respondent 
stated: 
If you’re in discovery research and you’re running a standardized process 
supplying leads to the CEDDs, the CEDDs are now very different in their 
requirements and they keep changing their requirements. So, if you’re running 
a huge automated process, feeding something that keeps changing its mind, 
there is tension in the system (Research Scientist, INT7/Company A). 
Although the reorganisation of GSK is still in a relatively early-stage of development,  
so its long-term benefits cannot be fully evaluated, it does represent a novel large-firm 
strategy for extracting value from new innovations and responding to the problem of 
innovation deficit and productivity decline. The GSK approach has been to 
fundamentally restructure internal operations and organisational management to expedite 
and improve efficiency in phase 2 development. However, another emerging strategy has 
been to exploit new translational processes and networked research activities through 
external collaboration with public sector organisations. An exemplar of this model has 
been the recently established TMRC, driven by the company Wyeth. 
4.2 Wyeth and the TMRC 
The TMRC is a broad, public–private initiative located in Scotland to extract value from 
translational medicine research and improve the development and delivery of innovative 
therapeutics. The TMRC has been described as the first of it’s kind, large-scale 
collaboration between government, academia and industry centred on Translational 
Medicine The collaboration, which has initial funding of £50 million (for a five-year 
period between April 2006 and 2011), involves the medical schools of four of Scotland’s 
leading research universities (Aberdeen, Dundee, Edinburgh and Glasgow);  
the associated cities’ health boards (NHS Scotland Grampian, Greater Glasgow, Lothian 
and Tayside); Scotland’s economic development agency, Scottish Enterprise and the 
global pharmaceutical company Wyeth. As successful therapeutic innovation has become 
increasingly difficult due to a confluence of scientific, regulatory and policy challenges; 
industry and the public health sector are increasingly embracing translational medicine as 
a potential strategy for improving the health innovation cycle. 
The TMRC was established on 1 April 2006 with the broad aim to develop  
and exploit a world leading network of clinical and scientific excellence throughout 
Scotland to contribute to the discovery, development and distribution of new diagnostics 
and therapeutics. A major part of TMRC involves the discovery of biomarkers for the 
diagnosis and monitoring of human diseases. The rationale behind the public–private 
organisational model was recognition that successful drug development requires  
close interaction and sharing of knowledge and expertise between a variety of institutions 
involved in the complex innovation cycle – global pharmaceutical companies, research 
universities, healthcare providers and public funding bodies (Gambardella et al., 2000). 
Scotland’s existing reputation for life science innovation and strong clinical 
infrastructure, particularly the highly integrated National Health Service and existing 
Networks of Clinical Excellence, helped Scotland attract the Wyeth deal  
(see Scottish Enterprise Report, 2005). Wyeth led the development of the collaboration 
in order to exploit translational medicine and biomarkers research to help it improve  
decision-making on its compounds. 
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The TMRC involves the establishment of a core research laboratory linking with four 
major academic Centres; as well as four NHS Trusts and Scotland’s Clinical Research 
Network. The basic idea is to combine the resources and expertise of the various funding 
partners and research institutions to conduct approximately 100 translational research 
projects in the initial five years. Most of the individual projects are focused on basic 
research, but some will involve investigation-driven therapeutic interventions focused on 
nominated Wyeth compounds. Figure 4 illustrates the basic structure of the model and 
the relationships of the key organisations involved. 
Figure 4 TMRC structure 
 
Source: Created by author using publicly available information and data from 
interview with TMRC representative. 
Wyeth and Scottish Enterprise are the two principal sponsors of TMRC. Each has 
provided core funding for the initial five years of the collaboration. The primary role of 
Scottish Enterprise is to act as facilitator and investor while Wyeth, in addition to 
providing core funding, will be a more active partner, using the collaboration to build on 
its existing expertise and commitment to translational medicine. By participating in the 
collaboration, Wyeth aims to, 
1 identify groups of patients more likely to respond to a therapy 
2 discover the optimal dosing regime for many of its products 
3 identify and validate biomarkers to help predict drug efficacy and adverse 
effects. 
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The innovation challenge Wyeth hopes to address through its involvement in the 
collaboration is how best to identify the most promising drug candidates earlier in 
development so the cost of late-stage failure can be avoided. 
The role of the four Centres of Excellence is to design and conduct the translational 
medicine studies. Teams of clinical and scientific researchers at each university are 
conducting clinical and scientific research on cardiovascular disease, neurosciences, 
women’s health, inflammation, oncology, bone disease and diabetes. These studies are 
focused on the discovery and validation of relevant biomarkers. The Centres also have a 
leadership and governance role in developing and integrating of links between the 
university faculties and the collaborative partners. 
The role of NHS Scotland and the Clinical Research Network is to contribute, in 
collaboration with the Centres of Excellence, clinical expertise and resources relevant to 
the biomarker studies. Furthermore, these bodies play an active role in ethics and 
research management, particularly in the context of clinical trials and ethical access to 
patient specific data and samples. Scotland’s NHS has already successfully developed 
new standardised methods of clinical data collection, storage and analysis that can 
facilitate basic research, and their knowledge and expertise in clinical trial design and 
ethical approval is expected to make a significant contribution to the collaboration.  
In essence, the various NHS partners provide the important link to the patients and 
clinical samples that will be crucial to the success of translational medicine. 
At the centre of the TMRC is the Central Research Laboratory, which is located at 
the University of Dundee. The laboratory’s research scientists are responsible for specific 
laboratory-based analyses of TMRC clinical research projects carried out in the other 
academic centres. A major role of the laboratory is to provide a new level of 
standardisation to the clinical samples that are sourced via research activities at the 
Centres of Excellence. The laboratory also conducts tests for translational studies  
(these are not traditional phases 1–3 studies) sponsored specifically for the development 
of Wyeth compounds. The laboratory has built up strong capabilities in proteomics, 
analytical biochemistry and bio-informatics. The Central Research Laboratory 
comprises: 
1 a basic research laboratory: that provides biomarker discovery, bioinformatics 
capabilities, assay development and core services to the other collaborating 
partners 
2 a clinical laboratory: that conducts exploratory biomarker studies including: 
optimisation of biomarker assays, analytical method validation and clinical 
sample handling, bio-banking and processing and analyses of clinical samples 
3 a clinical research interface: that connects the TMRC and the Scottish Clinical 
Research Network and coordinates research study design, data management and 
identification of external collaborators for the translational studies. 
TMRI Ltd is the company that has been set up as the delivery mechanism for the 
collaboration. It has two main functions. Firstly, TMRI is responsible for distributing the 
funding from Wyeth and Scottish Enterprise to the individual organisations involved in 
the collaboration. Secondly, TMRI has a specific role in exploiting outputs from  
the collaboration. It will evaluate and market the Intellectual Property generated from the 
research conducted by the universities and the NHS for specific fields of use.  
Overall coordination and management of the collaboration and its research is conducted 
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by a Steering Committee and Scientific Review Board. Both have representatives from 
each of the collaborating partners and determine the broad strategic aims of the 
collaboration and approve/monitor the specific translational projects. 
For Wyeth, the principal aim of TMRC is to accelerate the mid-stage drug 
development process so that safe and effective compounds can be more quickly and 
efficiently identified for late stage drug development.  It hopes to achieve this through 
better integration of basic and clinical science. Wyeth expects to benefit from access to 
external resources and expertise (biomarker studies, pharmacogenetics, tissue samples 
and clinical trial management, etc.) to help it successfully develop in-house R&D 
compounds. This model provides a flexible, outsourced organisational structure to 
facilitate internal drug discovery and development processes. Rather than fundamentally 
reorganise internal organisational and management processes, as was the case at GSK, 
the TMRC model provides an additional strategic option run in parallel to conventional 
in-house R&D. Of course, the benefits of TMRC are not considered to be exclusive  
to Wyeth. The other partners believe that the generation of valuable IP, increased  
funding for scientific research, and the broader wealth creation and inward investment 
that will be attracted to Scotland as a result of the collaboration, will bring important 
public benefits. 
The TMRC attempts to address a number of specific roadblocks or barriers that 
currently undermine successful health innovation. Two are particularly important. 
Firstly, for discovery research, the collaboration builds on and exploits the academic and 
public research base, including both basic and clinical research. The funding and support 
for a new, highly networked multicentred research infrastructure is expected to overcome 
the problem of how best to share, integrate and manage diverse public and private 
resources, knowledge and expertise to improve the health innovation cycle. Secondly, the 
problem of interoperability and integration of data is a major roadblock to successful 
health innovation, particularly in the context of the life sciences. The role of the  
Central Research Laboratory and the Centres of Excellence to develop new biomedical 
technologies and standardised methodologies and, in partnership with the NHS and 
clinical networks, to access patient data and better integrate clinical knowledge and 
expertise, is expected to meet this challenge. The central research laboratory is 
developing standardised procedures for the multicentred research projects so that,  
for example, the proteomics work conducted in Aberdeen uses the same methodology 
and validation criteria as that conducted in Glasgow. 
The primary strength of the TMRC appears to be its collective and integrative 
strategy for developing and applying basic science and technology to promote health 
innovation and mitigate the phase 2 attrition rate for new compounds. By combining the 
resources and expertise of a major pharmaceutical company with existing publicly 
funded institutions, this initiative could be a potential model of best practice for 
translational medicine. Wyeth is not simply establishing a new R&D centre or funding a 
single facility or project. Rather, it is buying into a broad collaborative network that is 
expected to grow organically. 
One potential weakness of the initiative, however, is that its organisational structure 
is so complex, and some of its objectives ambiguous and diverse, that it may find it 
difficult to deliver on its promises. The success of TMRC will depend largely on how 
well the participating organisations and their research staff work together on the core 
research projects and successfully translate the basic science into deliverable products. 
Furthermore, it is clear that the principal interest of Wyeth is to provide a model for 
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improving its mid-stage R&D efficiency, which is perhaps far less ambitious than the 
other public partners. While the collaboration is likely to meet the functional 
requirements of Wyeth, and will therefore be considered an industry success story, it is 
not at all certain that the broader goals of the public partners will be accomplished. There 
may also be a number of external factors that could undermine the success of TMRC as a 
potential R&D model. Drug development is, by its very nature, subject to much external 
uncertainty. In particular, market developments and regulatory changes might affect the 
success of the TMRC. These include: 
1 more stringent, and unforeseeable, regulations on how patients may be accessed 
and used for clinical trials 
2 new forms of privacy legislation to protect certain forms of clinical data, 
particularly genetic data 
3 external commercial pressures on Wyeth could, potentially, affect its future 
commitment to TMRC. 
5 Discussion and conclusions 
The evolution of the pharmaceutical industry over the past two decades – driven largely 
by the emergence of new technological trajectories, therapeutic options and confluence 
of external commercial challenges – has been characterised by growing firm 
differentiation in terms of strategic management and organisational restructuring. There 
appears to be significant variation in the range and scope of individual firms’ in-house 
capacity for biologics (Mittra, 2005), and their success in responding to the challenges of 
a capricious external operating environment. Although all the major pharmaceutical 
companies have made a significant investment in life science technologies to facilitate 
discovery and early stage R&D, more fundamental organisational changes and 
experiments with new innovation models have also been pursued by firms in response to 
declining productivity, inefficiencies in the middle stages of R&D, and the persistent 
problem of phase 2 attrition rates. 
Interview accounts reveal that firms’ R&D strategies and choice of therapeutic 
priorities are shaped by their particular histories, current research capabilities and 
expectations about future research trajectories. One respondent stated: 
You don’t start off with a blank sheet of paper. You inherit a portfolio of R&D 
so there is a momentum that kind of drives you to do more of the same. And 
companies historically have built varying portfolios. Bristol Myers Squibb 
always had a great strength in cancer research. Beecham essentially was an 
anti-infective company, so it takes a great amount of courage to move from that 
initial portfolio … In terms of making investment decisions about moving into 
new areas or continuing in a current area, or indeed discontinuing.  The most 
important driver is the available science and what you expect to be the 
available science in the average market. So companies will often make 
significant R&D decisions because they believe they have a particular piece of 
scientific capital – they’ve discovered a receptor or they’ve got a collaboration 
with an academic or SME that is leading them in a new way, or they’ve spotted 
something that they think no one else has … Of course, that investment would 
not be allowed to proceed very far without a perceived market (Former Head of 
R&D Policy, INT1/Company A).  
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In what is a highly competitive market, firms must increasingly build on their existing 
capabilities and acquire a commercial advantage by developing novel therapies for a 
high-value market. In their evolutionary analysis of drug R&D, Tsinopoulos and 
McCarthy (2002) argue that individual organisations, and their particular R&D 
strategies, have their own particular success rate, as measured by frequency of new drugs 
delivered to market. Differences in success rates may provide evidence for the variation 
and ‘fitness’ of different strategies. In this context, strategies refer to R&D concentration, 
therapeutic focus; merger, acquisition and strategic alliance behaviour and science and 
technology capabilities. 
However, many of the respondents admitted that companies were finding it difficult 
to make the paradigm shift from conventional small molecule therapies to biologics. 
Indeed, small molecule compounds continue to dominate large firms’ R&D pipelines. 
Nevertheless, all agreed that the balance was slowly shifting, and that experiments with 
new R&D models were in some significant sense an attempt to capitalise on the 
emerging opportunities provided by the life sciences. Nevertheless, questions remain 
about the broader benefits of organisational restructuring and its implications for 
innovation. 
The case studies of GSK and Wyeth exemplify two different strategies for 
responding to the current challenges of drug development and the need to better exploit 
the potential of the life sciences for therapeutic development. Although GSK was not 
unique in decentralising R&D through a networked hub structure, and reducing the size 
of the experimental unit, it has perhaps take this model further than most of its major 
competitors. However, while such models can contribute to greater R&D efficiency and 
allow companies to better exploit translational processes, they can also engender 
‘organisational inertia’ as knowledge flows and coordination follow the patterns of the 
antecedent structure if personnel fail to adapt to the new working practices (Criscuolo 
and Narula, forthcoming). Similarly, Wyeth is certainly not unique amongst the large 
pharmaceutical firms in developing public–private partnerships to facilitate internal 
R&D. Indeed, much of the research for diseases of the developing world involve 
partnerships between a diverse range of commercial and public research organisations 
and health care providers (Chataway et al., 2007). However, the novelty of the Wyeth 
and TMRC case study is the range of institutions involved, the basic organisational 
structure of the initiative and, crucially, the fact that Wyeth successfully established a 
long-term partnership that promises to directly contribute to resolving a range of internal 
R&D challenges; particularly phase 2 attrition. 
However, it remains unclear whether the emergence of these new organisational 
models is predominantly a response to the difficulties large firms currently face, such as 
regulatory burdens, escalating costs of R&D and diminishing returns on investment; 
exhaustion of conventional science and technology; challenges to the blockbuster model 
of drug development, patent exposure, etc., or alternatively a revolutionary attempt to 
move the industry forward through a new life science-based innovation trajectory.  
Or perhaps the impetus for such restructuring is related, in part, to both. As the current 
innovation system for both conventional therapies and emerging technologies is subject 
to continuing turbulence, there have been shifts in the balance of power and competitive 
advantage within the sector (Tait and Mittra, 2004). In this context, new experimental 
models for science, technology and strategic management can be seen as defensive or 
reactionary strategies to resolve core R&D problems. However, companies do also see 
the positive benefits of exploiting new therapeutic options provided by genomics and 
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biotechnology, some of which may disrupt conventional strategies associated with small 
molecule R&D. In this context, decentralised R&D networks and new public–private 
partnerships for translational medicine can enable large firms to better utilise existing  
in-house capabilities, as well as build new capabilities by securing access to the 
knowledge, resources and expertise of external innovators. 
Of course, even if the large firms can better exploit the potential of the life sciences 
through internal organisational restructuring or reassessment of traditional therapeutic 
and technological priorities and collaborative options, the social and regulatory 
environment for pharmaceuticals will continue to exert external pressure on firms and 
shape their innovation strategies. The regulatory and policy environment continues to 
drive strategic decision-making within firms – in this sense it occupies a powerful 
position outside the core innovation system (Tait, 2007) – and can have a significant 
effect on the type of therapies developed and their commercial value. As regulatory 
regimes for many technologies that could be disruptive for the pharmaceutical industry, 
such as stem cells, are yet to be fully developed, the strategic reorientation of some of the 
large multinationals are clearly not going to solve all the problems associated with 
innovation in the age of biomedicine. Furthermore, the new models do not necessarily 
have a direct impact on pricing issues, patent protection and the difficulties/costs 
associated with conducting large clinical trials. 
Nevertheless, many of the large firms have now signalled their commitment to the 
life sciences and recognised key problems with the traditional, centralised R&D model. 
Many within industry have also expressed the belief that the traditional small-molecule 
blockbuster model is unsustainable. Variation within the large firm sector, in terms of 
how technology and therapy areas are prioritised and how R&D is managed, suggests 
that Big Pharma should no longer be treated as a homogenous sector. It is important to 
look at the specific strategies large firms are implementing, in the context of their historic 
capabilities and strategic vision for future R&D requirements, and evaluate them in terms 
of long-term impact on both early-stage efficiency and number/type of new products 
successfully delivered to market. Although there does appear to be a productivity  
crisis in the sector, the long-lead times in pharmaceutical R&D mean that the precise 
benefits of current restructuring initiatives will take some time to observe. 
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1Primary data were derived from 11 in-depth interviews with scientists and managers who 
currently, or have recently, held senior management positions within large pharmaceutical 
companies. Four top-ten global pharmaceutical companies are represented in the sample, but 
due to confidentiality arrangements they are not always named in the text. Data were collected 
in 2005 as part of an ongoing project – conducted with the ESRC Innogen Centre, University 
of Edinburgh – on Innovation Processes in Life Science Industries. All respondents requested 
anonymity, but their area of expertise and/or job title is indicated where appropriate. 
Secondary data were derived from a variety of sources including: PhRMA, FDA, IMS Health, 
Nature Biotechnology, Deutsche Bank AG investment reports and company websites and 
annual reports. Data for the GSK case study were derived from company websites  
and publicly available data, and the TMRC case study also included an interview and extended 
communication with some key personnel involved in the Initiative. 
